SenesTech, Inc. - Common Stock (SNES)

SenesTech (NASDAQ:SNES) reported a 51% increase in revenue for the first nine months of 2024, totaling $1.4 million, driven by strong sales of its Evolve Rat and Evolve Mouse products. Gross margins improved to 65% in Q3 2024, up from 49% in the same quarter last year, due to enhanced manufacturing efficiency. The company’s operating expenses decreased by 12%, and its adjusted EBITDA loss was the smallest in its history, reducing cash burn by 21%. Evolve Rat, launched in early 2024, now accounts for 52% of Q3 revenue, and the company has expanded sales through e-commerce platforms like Amazon and Walmart. Additionally, SenesTech is expanding into international markets, securing significant orders from distributors in Hong Kong and the Netherlands. The company is also exploring municipal opportunities, including a rat contraception pilot program in New York City.

SenesTech (NASDAQ: SNES), the leader in birth control to manage rodent pest populations, is reporting that the New York City Council has approved a bill to implement a rat contraception pilot program. According to the announcement, the bill stipulates that “rat contraceptive” means an agent for the reduction of reproductive capacity in rats; the bill also calls for the use of an agent approved by the U.S. Environment Protection Agency (“EPA”). Currently, SenesTech is the only manufacturer of products that meet this requirement. The bill calls for city departments to begin the program, which will run for at least 12 months in two rat-mitigation zones and a comparable area, within 180 days of enactment.

SenesTech (NASDAQ: SNES), the rodent fertility-control experts and inventors of the only EPA-registered contraceptive for male and female rats, will be spotlighted at the upcoming Lytham Partners Fall 2024 Investor Conference. Company officials are slated to participate in a webcast presentation during the event, which will be held Oct. 1, 2024; the company’s presentation is scheduled to begin at 11 a.m. ET. In addition, SenesTech representatives will host online one-on-one meetings with investors during the virtual conference.

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, recently issued new unregistered warrants to purchase up to an aggregate of 1,011,004 shares of common stock at $4.35 per unit in a private placement. The company also closed on an exercise of certain existing warrants to purchase 505,502 shares of its common stock at a reduced exercise price of $4.60 per unit, raising approximately $2.3 million in aggregate gross proceeds. SenesTech intends to use the net proceeds from this transaction for working capital and general corporate purposes ( https://ibn.fm/o12H7 ).

SenesTech (NASDAQ: SNES), the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, has closed on an exercise of certain existing warrants. The exercise consisted of purchasing 505,502 shares of the company’s common stock at a reduced exercise price of $4.60 per share. The company also issued new warrants. According to the announcement, gross proceeds from the exercise of the existing warrants totaled an estimated $2.3 million before fees and deductions. The company plans to use the funds from the transaction for working capital and general corporate purposes, including the continued rollout of its Evolve(R) product line. H.C. Wainwright acted as the exclusive placement agent for the transaction.

SenesTech (NASDAQ: SNES), the inventor of ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, as well as Evolve(R) and Evolve Mouse(R), EPA-designated minimum risk contraceptives for rodents, recently reported financial results for its second quarter of fiscal 2024, ended June 30, 2024. In addition, Joel Fruendt, President and CEO of SenesTech, and Tom Chesterman, CFO of SenesTech, hosted a conference call ( https://ibn.fm/1MQaT ).

SenesTech’s (NASDAQ: SNES) flagship product, Evolve(TM), has repeatedly demonstrated an effective rat control alternative to current market offerings. “The active ingredient in the product has been scientifically proven to reduce rodent fertility, ultimately offering a more proactive approach to addressing the growing rat problem, as opposed to a more reactive approach, as is the case with poisons and traps. The obvious argument is that it’s better to control reproduction than to kill rats after they are born,” reads a recent article.

In 2023, it was estimated that New York City had roughly 3 million rats, an increase of almost 1 million over the last ten years. The situation has gotten so bad that the city has become almost synonymous with rat infestation problems.

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control(R), is reporting on its second-quarter 2024 financial results. According to the report, the company saw record revenue of $874,000 in the first half of 2024, a 62% increase when compared to the first half of 2023, as well as improvement in margin percentages.

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, has announced plans for a conference call and webcast to be held on Aug. 8, 2024, at 5 p.m. ET. According to the announcement, the company plans to release its financial results for second quarter 2024 after market close on the same day. During the conference call, company leaders will review those results. Those who wish to access the call may dial (844) 308-3351 or (412) 317-5407. A replay of the event will be available on the company website for seven days. Those wishing to access the replay may dial (877) 344-7529 or (412) 317-0088, and then use replay access code 6578863. A webcast replay will be available on the company’s website for 90 days.

Back in 2020, a study published by Tufts Wildlife Clinic and Cummings School of Veterinary Medicine showed that 100% of the Red-tailed Hawks admitted into their clinic tested positive for rodenticides. Earlier this year, Flaco, a famous Eurasian eagle owl that lived in Central Park, was found dead. A necropsy would later reveal that he was exposed to four different second-generation anticoagulant rodenticides (“SGARs”). It shed light on the use of rodenticides for rodent population control and its impact beyond rodents and onto a broader ecosystem that includes birds and other animals ( https://ibn.fm/m6wJW ).

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, is spotlighted in the latest episode from The GotStock Podcast, which is released by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. SenesTech president and CEO Joel Fruendt is the featured guest on the most recent episode, which is hosted by IBN’s Carmel Fisher. During the interview, Fruendt provides an overview of the company and its business model, noting that SenesTech’s mission is to help manage animal-pest populations, particularly rodents, through fertility control. He explained that the company’s proprietary ContraPest(R) is based on a patented, proven technology that reduces or eliminates fertility in both females and males. Part of IBN’s commitment to provide specialized content distribution via widespread syndication channels, The GotStocks Podcast puts the small-cap sector in the limelight with in-depth interviews featuring executives in key companies. “Right now, we have labels for rats and mice, and we attack the problem at its root cause – reproduction,” said SenesTech president and CEO Joel Fruendt. “I’ll start out with this fact that usually leaves people with their jaws dropping: two rats, in one year, can become 15,000. That is really the basis for our product. You cannot poison, trap or drown rats fast enough without addressing the reproductive rate, and that is really why our product is in the news a lot right now and why we’re getting such success out in the marketplace.”

Following New York City’s recent hard stance in the fight against rodents in the city, its leadership has been under backlash, mainly from People for the Ethical Treatment of Animals (“PETA”). The organization blamed the rat problem on the city’s lack of proper systems and infrastructure to manage garbage, which ultimately attracts rats in the first place. But it has also raised concerns about the inhumane approach the city has taken to fight the rodent problem, such as poisons and traps, a move that has been termed as “villainizing rats for problems created by humans” ( https://ibn.fm/lsmj1 ).

SenesTech (NASDAQ: SNES), a rodent fertility control product provider and the inventor of the only EPA-registered contraceptive for male and female rats, just announced the deployment of its Evolve(TM) flagship product to the U.S. Virgin Islands in an effort administered by The Wild Ecology Group . This represents a new growth opportunity for the company, given that Wild Ecology will place regular orders as it seeks to address the growing invasive rat problem ( https://ibn.fm/tqBiN ).

In the fiscal year 2023, calls to 3-1-1 in Washington D.C. regarding rat sightings and complaints hit 16,391, up from 8,107 in 2020 ( https://ibn.fm/0j62f ). For the state government, the hotline was set up as a means to deal with the growing rat problem, which did help deal with the situation, but only to a certain extent. Similar efforts to curb the rat infestation problem were translated to other cities across the country, with New York declaring the rodents as “public enemy No. 1” and targeting rat mitigation zones in neighborhoods with historically high rat activity ( https://ibn.fm/tJ4Gx ).

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, is scheduled to present at the 72nd Emerging Growth Conference , hosted by leading independent small cap media portal EmergingGrowth.com. Taking place on June 12 – 13, 2024, the event identifies companies in a wide range of growth sectors with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth. Joel L. Fruendt, president, CEO and director of SenesTech is scheduled to provide a keynote speech at the conference starting at 3:20 p.m. ET on June 12.

SenesTech (NASDAQ: SNES) is a rodent fertility control product provider and the inventor of the only EPA-registered contraceptive for male and female rats. The company has been rapidly growing with its unique solutions, defined by its two main offerings – ContraPest(R) liquid and Evolve(TM) Soft Bait, both of which have demonstrated impressive results in controlling pest populations through fertility control. “The city of New York is exploring the use of Evolve, owing to its shelf life, safety profile and overall effectiveness… With the introduction of a new bill by an Upper West Side Council Member, the city is set to, hopefully once and for all, deal with the rat menace that has posed a challenge for every generation of New Yorkers,” a recent article reads. “SenesTech is optimistic that its Evolve Soft Bait will yield impressive results, highlighting the product’s overall efficacy while stamping the company’s position as a leader in its space. Already, the company has seen major interest in its Evolve product, and this move by the city of New York is seen as affirming the product’s superiority while serving as a sign of even bigger things to come.”

SenesTech (NASDAQ: SNES), a rodent fertility control product provider and the inventor of the only EPA-registered contraceptive for male and female rats, just announced the launch of its dedicated online store on Amazon. As the world’s largest online retailer, this move brings SenesTech and its products closer to consumers, marking a significant step forward in distributing its flagship Evolve(TM) soft bait ( https://ibn.fm/cJrCf ).

SenesTech (NASDAQ: SNES), a player in the field of fertility control for managing animal-pest populations, has launched its Evolve fertility-control solution for rats on Amazon. The company called the move a “significant advancement in the distribution of Evolve, the company’s innovative minimum-risk soft bait designed for proactive rat control.” Evolve, which contains an active ingredient proven to reduce rodent fertility, targets the root cause of rodent overpopulation by reducing fertility rates rather than using poisons or other toxic substances. “The launch on Amazon, the world’s largest online retailer, significantly enhances the accessibility of Evolve to everyday consumers,” the announcement stated. “The product was previously available primarily to professionals. Evolve’s presence on Amazon allows a broader audience to adopt this effective pest control solution. This move is expected to drive substantial growth in SenesTech’s market share, leveraging the convenience and reach of e-commerce.”

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, is announcing participation at the Lytham Partners Spring 2024 Investor Conference. The event will take place virtually on Thursday, May 30, 2024. Joel Fruendt, CEO of SenesTech, and Tom Chesterman, CFO of SenesTech, will participate in a webcasted presentation scheduled for 11:45 a.m. ET. The webcast will also be available for replay following the event. SenesTech’s management will also host virtual one-on-one meetings with investors throughout the event. See the announcement for information about how to arrange a one-on-one meeting with management.

SenesTech (NASDAQ: SNES), the provider of a one-of-a-kind technology for controlling animal pest populations through fertility control and the only manufacturer of commercially available, EPA-registered Rat Birth Control(R), recently announced financial results for the first quarter of 2024, ended March 31, 2024, and released operational highlights ( https://ibn.fm/kxzyA ). During this reporting period, the company reported record revenue of $415,000, a year-over-year increase of 78% compared to the first quarter of 2023. This was also a 41% increase sequentially from the fourth quarter of 2023.

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, has launched a dedicated online store on Amazon for Evolve(TM), its minimum-risk, soft bait for the proactive control of rats. Calling the move a “significant step forward in the distribution of Evolve,” the company noted that Evolve addresses the fundamental issue of rodent overpopulation by focusing on their rapid reproduction rates. Numerous independent studies indicate that the active ingredient in Evolve effectively reduces fertility in rodents. Research shows that two rats with sufficient food, water and shelter can produce up to 15,000 offspring within the year, and Evolve is designed to prevent that. “Evolve isn’t just a product; it’s a paradigm shift in pest control,” said SenesTech president and CEO Joel Fruendt in the press release. “Our mission from day one has been to provide consumers and professionals with a safe, effective and convenient alternative to traditional poison-heavy pest control. Evolve has already garnered acclaim in the professional market since its launch at the beginning of the year. Now, it’s poised to revolutionize how everyday consumers can safely and proactively combat rodent pests with its availability on Amazon.”

SenesTech (NASDAQ: SNES), the inventor of the only EPA-registered contraceptive for male and female rats, recognizes the risks associated with growing rodent populations in cities and areas with a substantial human population. “With its fertility control products, SenesTech offers a proven way for entire cities and urban areas to reduce rat populations by over 90%. Available in a variety of delivery systems, SenesTech’s products allow for easy and efficient product deployment, an approach that is achieving significant acceptance in the market. SenesTech’s approach is much needed throughout the industrialized and agricultural world, particularly factoring in how rodents can directly transmit a range of pathogens and diseases… SenesTech has been advocating non-lethal rodent birth control products added to or separate from existing integrated pest management plans. Their products can be used separately, or in conjunction with additional rodent control methods,” a recent article reads. “The most [effective approach] is combining the elements of integrated pest management and having them work together and support each other,” Joel Fruendt, SenesTech’s CEO, was quoted as saying.

SenesTech (NASDAQ: SNES), a rodent fertility control product provider and the inventor of the only EPA-registered contraceptive for male and female rats, is pleased to announce the launch of its Evolve(TM) Mouse product, the company’s official entry into the mouse contraceptive market. This marks an extension of the company’s Evolve fertility product line, with its proven efficacy in reducing rat populations. Evolve was only launched in January 2024 and has already seen rapid and growing adoption in the field, including its application in controlling the highly publicized rat problem in New York City.

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control(R) products, is reporting its financial and operational results for first quarter 2024. Highlights of the report include record quarterly revenues of $415,000, up 78% from Q1 2023; Evolve(TM) becoming the company’s best-selling product, making up more than 50% of this quarter’s revenue; securing distribution and agreements as well as initial purchase orders with several grain-management and open-field agricultural distributors and pest-management industry distributors; global expansion with new sales in Hong Kong, Macau, the United Arab Emirates, Singapore, Australia, New Zealand and The Netherlands; the introduction of Evolve in convenient 1.5- and 3-lb. pouches; and the launch of Evolve(TM) Mouse to control mouse infestations. “I am extremely pleased with the rapid revenue growth during the first quarter of 78%, resulting in record quarterly revenues, driven by the rapid adoption in the marketplace of Evolve, our all-new soft bait product to control rat populations by restricting fertility,” said SenesTech president and CEO Joel Fruendt in the press release. “During the first quarter, Evolve accounted for more than 50% of sales, as distributors and end customers have quickly understood the benefits our new solution provides. . . . The last few months have been the most exciting and productive time in SenesTech’s history. . . . We are extremely pleased with the progress the team has made in 2024 and look forward to the positive impact the many recent initiatives we have implemented will produce.”